|
Familial
Shar-Pei Fever
(FSF)
Before you read Dr. Vidt's summary below on FSF, let me give
you my thoughts.
I have been breeding for over 20 years.
I have had dogs with FSF, in fact I had one die last year at
14 years of age.
IT IS NOT A DEATH SENTENCE.
Many many other breeders agree with me.
FSF does not
automatically mean Amyloidosis
I have an 8 year old
that gets them, it lasts for 12 hours and is then gone.
I have had 3 dogs here that died of Amyloidosis, not one of
them ever had FSF. Those that I have had FSF, did not die from Amyloidosis.
If your pet gets a bout of FSF, unless the temperature
reaches 106-107 (normal is 101) give them an ASCRIPTIN. This brings down the
fever and takes away the pain.
DO NOT PANIC, this is not necessarily a death sentence,
PLEASE CALL YOUR BREEDER!!!!!!!!!!!!!!!!!!
Written by: Jeff Vidt, DVM
Familial Shar-Pei Fever (FSF) is a hereditary inflammatory disorder seen
in Shar-Pei. It is inherited as an autosomal recessive condition.
Clinical signs:
Episodic fever is the most important and consistent clinical sign of this
disorder. The temperature commonly is in the 105-107°F range. The fever is
generally self-limiting lasting 12-36 hours. Another common clinical sign often
accompanying the fever is swelling of a joint, usually the hock (tibiotarsal)
joint and is known as Swollen Hock Syndrome (SHS). This painful, hot swelling
can also involve the carpus (wrist) and the lips. Dogs with FSF are sick -- they
are reluctant to move and when they do walk they have a characteristic "walking
on eggs" gait. They often are painful in the abdomen and have a characteristic "roached"
back.
Pathogenesis:
What we do know about this disease is as follows:
-
Shar-Pei with FSF have
increased levels of the cytokine Interleukin-6 (IL-6). IL-6 is involved with
the fever response and and is an integral part of triggering the production
of Acute Phase Reactant Proteins by the liver. IL-6 is also involved in the
Systemic Inflammatory Response Syndrome (SIRS). Dysregulation of IL-6 is the
cause of much of the disease in Shar-Pei with FSF. IL-6 also plays a major
role in the body's stress response and serves to "prime" the immune system.
-
Shar-Pei with FSF are
at risk from early death from systemic amyloidosis.
About 25% of the FSF
dogs will develop renal failure including renal amyloidosis -- a smaller
percentage will develop hepatic amyloidosis. This is usually seen in
Shar-Pei between the ages of 2-5 years of age. They also seem more
susceptible to immune-mediated kidney disease such as membranous glomerulonephritis, protein-losing glomerulopathies, DIC, thromboembolic
phenomena such as mesenteric, splenic and pulmonary embolism and
Streptococcal Toxic Shock Syndrome (STSS).
-
FSF in Shar-Pei was
hypothesized to be an animal model of Familial Mediterranean Fever (FMF) in
humans. Recent work indicates this is not true, although FSF is very similar
to FMF in man.
-
FSF is a
heredofamilial disease with a genetic basis. It appears to be inherited as
an autosomal recessive condition.
Laboratory Findings:
Unfortunately there are no blood test, etc. which are specific for FSF.
During a
fever episode there will often be an increased white blood cell count,
an
increase in liver enzyme levels and other non-specific findings. Work done by
Dr. Gary Johnson at the University of Missouri College of Veterinary Medicine to
develop a DNA blood test to screen for the disease was unsuccessful and the
research effort will still continue.
Treatment:
It is very important to monitor the temperature in this condition. Initially,
fever can be treated using aspirin. Usually a regular strength adult aspirin is
given every 6 hours for the first 24 hours and then twice a day for 3-5 day
thereafter. In rare cases where aspirin doesn't work of for extremely high
fevers, dipyrone is given. Some patients will require supportive care with
intravenous fluid therapy and in extreme cases emergency treatment similar to
heat stroke treatment. Antibiotics are not normally indicated in this condition.
Colchicine:
Colchicine is a drug that has been in use in people with FMF to prevent
amyloidosis. It is currently being recommended in Shar-Pei with FSF for the same
purpose. No studies have been completed to determine if it is useful for this
purpose in the Shar-Pei or not. The clinical impression is that it does help.
Those dogs on colchicine seem to have fewer FSF episodes and less severe signs
while on the drug. Side-effects appear to be minimal at this time and are
primarily gastrointestinal such as vomiting, diarrhea, anorexia (decreased
appetite), etc.
Prevention:
Shar-Pei with FSF only show symptoms sporadically. It would appear that there
are "triggers" involved in initiation of the FSF episodes. One of the major
triggers appears to be stress. This may be a dog training class, a dog show,
another illness, a dog in heat, excessive exercise, etc. If the owner can
recognize these triggers and take steps to avoid them the number of FSF episodes
can often be reduced. Diet does not appear to be helpful in prevention of FSF or
kidney disease. Surely diet has a role in the management of the kidney disease
once clinical signs are apparent. Low dose aspirin therapy may be useful in
decreasing the incidence of FSF and its severity as well. Aspirin may also be
useful as an adjunct therapy in the prevention of thromboembolism.
Monitoring:
Monitoring for the complications which often accompany FSF is one of the major
goals of the owner of an FSF dog. The primary and most consistent sequela to FSF
is kidney failure either due to immune-mediated kidney disease or renal
amyloidosis. I currently recommend monitoring a urinalysis every 3 months. The
sample should be collected first thing in the morning after the water has been
taken up overnight. I primarily look at the urine specific gravity which is a
measure of the concentration of the urine and the protein levers in the urine.
When the kidneys begin to fail the initial indication is a loss in the ability
to produce a concentrated urine. This occurs before there are blood changed
related to kidney failure. Increased water consumption, increased urination are
the clinical signs associated with the loss of concentrating ability, but these
signs are often not recognized. I also thing it is wise to do a blood panel
every 6-12 months and certainly do one in the urinalysis is abnormal. Weighing
your dog periodically is very important. We often don't recognize a significant
weight loss because it is very subtle over a longer period of time. Water
consumption and appetite are other important indicators to watch.
Complications of FSF:
We have already discussed the kidney complications in this condition. Other
Complications which have been documented include thromboembolism (mesenteric,
splenic, pulmonary), DIC (disseminated intravascular coagulation), SIRS
(systemic inflammatory response syndrome), MODS (multiple organ dysfunction
syndrome), STSS (streptococcal toxic shock syndrome), hypertension associated
with renal failure. Many of the deaths following an acute FSF episode are due to
these complications. No FSF episode should be treated lightly!
Diagnosis:
There is no specific diagnostic test for FSF at this time. Diagnosis is based on
the clinical sign of episodic fever in a Shar-Pei. I think every Shar-Pei that
dies should be autopsied to determine the cause of death, but this is even more
critical in cases involving FSF. Renal amyloidosis can only be diagnosed based
on kidney biopsy and staining with Congo Red stain. This stain is specific for
the presence of amyloid. Amyloid has been found in other tissues in Shar-Pei as
well so special staining should be requested on all tissues submitted for
histopathology.
Many dogs with FSF will
not have amyloid in the tissues at the time the tissues were harvested -- this
means the absence of amyloid in a biopsy specimen does not mean that dog will
not or would not have gone on to develop amyloidosis at a later time. To further
confuse the issue, not all Shar-Pei with amyloidosis have shown signs of FSF.
Future:
Research is currently underway at the University of Missouri College of
Veterinary Medicine by Dr. Gary Johnson to develop a DNA blood test. The gene
for human FMF was sequenced in the Fall of 1997 and with that information Dr.
Johnson had hoped to sequence the FSF gene. That information was applied by Dr.
Gary Johnson to FSF in a research project founded by the CSPCA Charitable Trust.
That project did determine that the mutations causing FMF in man do not exist in
FSF in the Shar-Pei, hence they are two distinct, although similar diseases.
There are other hereditary inflammatory fever disorders in man and Dr. Kastner
ant the National Institutes of Health are looking at the disorder with
information supplied by Dr. Tintle. Familial Hibernian Fever in man has also
been ruled out as the cause of FSF by Dr. Johnson with information supplied by
NIH. Work will continue to find the genetic mutation(s) responsible for FSF in
Shar-Pei.
As of this writing the mutation responsible for FSF has not been found. If a
test can be developed, a screening program can be established to screen breeding
stock and determine normal individuals, carriers and affected dogs. With this
information Shar-Pei breeders can gradually eliminate this genetic disease from
the breed. One of the major obstacles to research revolves around the
unpredictable phenotype of FSF. There is no consistent age range when clinical
signs develop, the clinical signs can be variable, some dogs develop
amyloidosis, some don't, etc. This makes it very difficult to use genetic
selection methods which are based on phenotype.
Recommendations:
All Shar-Pei with FSF should be on colchicine and be regularly monitored via
urine samples and blood work for development of complications. Dogs with FSF
should not be used in breeding programs and should be neutered. Dogs with a
family history of FSF should be on colchicine and monitored. Dogs with FSF
should be maintained as stress-free as possible.
Dr. Linda Tintle
UPDATE ON
RESEARCH AND REQUEST FOR SAMPLES FROM DOGS WITH FSF DURING A FEVER EVENT
AS WELL AS IN BETWEEN FSF EPISODES
As
part of our CSP Charitable Trust-AKC/CHF
funded study, Dr. Anne Avery is looking for
blood samples from dogs with FSF (Familial
Shar-Pei Fever) at the time they are spiking
a fever. Please have your veterinarian
obtain 6-10 ml of EDTA whole blood (lavender
top tube) and the serum from 3-5 ml blood
(red top or serum separator tube) and
contact Dr. Avery at (970) 491-1170 to
arrange overnight shipment of the samples
to: Dr. Anne Avery, Dept. of MIP, 1619
Campus Delivery, Fort Collins, CO 80523-1619
by overnight express. You will need to
provide a signed consent form, the dogs
AKC number and complete a questionnaire
which can be faxed or e-mailed to you.
Shipping costs via UPS will be covered by
the research grant
an
(account number will be provided for
billing) but there is no funding available
to reimburse you for veterinary expenses.
Please help. She also still needs
samples from ANY dog with a history of FSF
episodes. Your cooperation will benefit
your dog and the entire breed.
Preliminary results have shown that a
statistically significant greater number of
Shar-Pei with FSF or Shar-Pei with close
relatives with FSF/A have elevated
background levels of IL-6. Shar-Pei without
evidence of FSF and no close relatives with
FSF/A did not have statistically
significantly elevated background levels of
IL-6. This was shown in my study with
Cornell and confirmed by Dr. Avery's recent
testing. So far, it looks like SAA and
CRP levels are all over the place and do
not correlate with health or disease but
analysis is on-going. Also, no Shar-Pei
(with or without FSF) that Dr. Avery
examined had elevated levels of TNF-á.
Serum IL-10 and HA (hyaluronan or mucin)
levels are next. We do not know yet if
serum HA levels correlate with their
auto-inflammatory disease. All we can do at
this time is speculate which is why that
research is a priority. I am also working
to get Dr. Avery's study to include checking
levels of IL-1â as soon as possible because
this has been implicated in some of the
human periodic fever disorders. Since IL-6
is one of the main chemical signals to turn
on the acute phase reactant proteins (the
precursors of amyloid A), chronic elevation
of IL-6 in FSF patients is not a surprising
finding. My study with immunologists Ariel
Rivas and Fred
Quimby at Cornell in the early '90s
suggested that there may be problem with
down-regulation of IL-6 so we are going to
take another look at that (a blocked
receptor for an IL-6 inhibitor?)
The studies are as yet incomplete. S-P had
dramatically elevated levels of IL-6 and SAA
during fever events. We are looking for
samples from more dogs during events (see
above). These elevations are not unexpected
because these are the messengers of
inflammation but we want to compare their
response to normal controls to see if they
are exaggerated.
The problem with IL-6 as a test is that not
every dog with FSF had elevated background
levels - there may be a lot of false
negatives so I don't know how useful it
might prove as a diagnostic test. One of the
other cytokines yet to be examined may prove
to be more predictive. A specific genetic
mutation that is shared by all Shar-Pei with
FSF would be ideal the elusive holy
grail of tests. Linkage studies for this
will be starting as soon as we can get all
the information possible on the dogs in the
pedigrees being examined by Dr. Puppo at the
NIH. (Very soon).
My heartfelt thanks to
Barbara LaVere, Pat Zimmel-Roach, Alice Fix,
Dr. Jeff Vidt and all the members of the
Centennial Club in the Colorado area (too
numerous to list but without which Dr.
Avery's project would not be moving
forward!) and the many CSPCA members who
have so kindly taken the time to provide
information for the pedigree analysis
component of the DNA study at the NIH. Dr.
Avery told me today how enormously impressed
she is by the lengths to which Shar-Pei
breeders have been willing to go to help
with this project. Shar-Pei people are as
special as their dogs!
Dr. Linda Tintle
Wurtsboro Veterinary Clinic
163 Sullivan Street, PO Box 910
Wurtsboro,
New York 12790
wvc@warwick.net
www.wvc.vetsuite.com
April
14, 2006
|
|
|